Galderma Delivers Strong H1 2022 Results and Continued Innovation Across Its Leading Dermatology Portfolio

2022年08月31日 08:59:16 来自: (0)参与

ZUG, Switzerland--(BUSINESS WIRE)--Galderma:

Continued strong commercial and financial performance in a resilient market

  • Galderma delivered continued strong growth across product categories, with net sales up 15% year-on-year on a constant currency basis at 1,914 M USD
  • Particularly strong performance of Injectable Aesthetics and Dermo-cosmetics product categories with growth of 32% and 31% on a constant currency basis, respectively
  • Volume as a primary growth driver underpins confidence in the resilience and long-term growth fundamentals of the dermatology market
  • On track to deliver on 2022 guidance of 12-14% net sales and core EBITDA growth on a constant currency basis

Advancing innovation across its leading dermatology portfolio

  • Important clinical milestones achieved, including positive phase III results reinforcing the efficacy and safety of nemolizumab in prurigo nodularis, and positive phase III topline data release of RelabotulinumtoxinA (QM-1114), showing improved glabellar lines (frown) and lateral canthal lines (crow’s feet) with a rapid onset of action and a long duration
  • Significant launches across all product categories, including Alluzience®, the first ready-to-use liquid form of botulinum toxin type A in Europe; Twyneo®, the first ever tretinoin and benzoyl peroxide combination to treat facial acne; and Epsolay®, the first and only microencapsulated benzoyl peroxide topical treatment of bumps and blemishes of rosacea

“We are very pleased with how the company has performed in the first half of 2022 and we remain on track to deliver on our full-year guidance. Our performance demonstrates strong growth momentum despite challenging global conditions. We continue to advance innovation and science across our portfolio, with important clinical milestones reached for nemolizumab and RelabotulinumtoxinA, and significant new product launches. In a dermatology market that has proven resilient in the first half of the year, we believe Galderma is well positioned to meet consumer demand through its premiumization strategy and broad channel exposure.”

 

FLEMMING ØRNSKOV, M.D., MPH

CHIEF EXECUTIVE OFFICER

 
相关新闻
其它网友:空心 Vicious▽
评论:你若使用美人儿计,我就将计就计

猫扑网友:肆虐ヽ Ragingヽ
评论:婚外情可以是个浪漫的故事,但离婚则是一次惨痛的事故。

天猫网友:谢谢你给的痛
评论:今天情人节出去玩,卖花的小姑娘拉着我:“大哥哥,买花吧,一看就知道你是花心的人”……

本网网友:℡說好不見面
评论:黄瓜是用来拍的,人生是用来嗨的

凤凰网友:时光安好moon
评论:坐地铁,是一项糅合太极,柔道,缩骨功的综合性运动。

百度网友:迷局  Memory 
评论:我知道强扭的瓜不甜,但是本人就是不喜欢吃甜瓜。

淘宝网友:capital °故作
评论:人生没有彩排,每天都是直播;不仅收视率低,而且工资不高。

网易网友:你给的牵绊╮
评论:每当我找到了成功的钥匙,就有人把锁给换了。

腾讯网友:THOMAS 《死亡诗社》
评论:“高富帅官二代”这六个字,我想我只做到了第五个字。

天涯网友:心悲 2/2star°
评论:你要是嫁人,不要嫁给别人,也不要嫁给我

新闻转自网络媒体,如有侵权,请与我们联系:1160322105@qq.com责编:admin